DelveInsight's "Primary Ciliary Dyskinesia Market Insights, Epidemiology and Market Forecast-2028" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Primary Ciliary Dyskinesia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Primary Ciliary Dyskinesia (PCD) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017-2028


Primary Ciliary Dyskinesia - Disease Understanding and Treatment Algorithm

The DelveInsight Primary Ciliary Dyskinesia (PCD) market report gives the thorough understanding of the Primary Ciliary Dyskinesia (PCD) by including details such as disease definition, causes, symptoms, pathophysiology, and diagnostic trends. It also provides overview of treatment and management of the disease in the US, EU5 and Japan.

Primary ciliary dyskinesia (PCD) is an autosomal recessive genetic disorder caused by the impaired function of cilia of the respiratory tract epithelial cells, which may also involve other ciliated cells in the reproductive system of the male or female.


Primary Ciliary Dyskinesia Epidemiology

The Primary Ciliary Dyskinesia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and the prevalence based on clinical manifestations in the US, EU5 and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, and prevalence based on clinical manifestations) scenario of Primary Ciliary Dyskinesia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, total prevalent population of Primary Ciliary Dyskinesia in seven major markets was found to be 80,815 in 2017.?


Primary Ciliary Dyskinesia Drug Chapters

This segment of the PCD Drug report encloses the detailed analysis of the emerging drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.

At present, therapeutic approach of PCD involves symptomatic treatment. The PCD market forecast provided in the report solely focuses on the market revenue generated by the off-label systemic therapies, such as antibiotics, inhaled corticosteroids, rhDNase and bronchodilators. Till date no drug has obtained approval for the treatment of PCD. Detailed chapter for upcoming therapies like Vertex Pharmaceuticals novel inhibitor of the epithelial sodium channel (ENaC) VX-371, and other promising therapies such as POL6014 (Santhera Pharmaceuticals) have been covered in the report.


Primary Ciliary Dyskinesia (PCD) Market Outlook

The PCD market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers.

This segment gives a through detail of emerging therapies and other promising therapies by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Primary Ciliary Dyskinesia (PCD) in 7MM was found to be USD 490.66 million in 2017.


Primary Ciliary Dyskinesia (PCD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Primary Ciliary Dyskinesia (PCD) Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Primary Ciliary Dyskinesia (PCD) Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Market Size by Therapies

• Key Cross Competition


Primary Ciliary Dyskinesia (PCD) Report Assessment

• Pipeline Product Profiles

• Key Products and Key Players

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Primary Ciliary Dyskinesia (PCD) market.

• Organize sales and marketing efforts by identifying the best opportunities for Primary Ciliary Dyskinesia (PCD) market.

• To understand the future market competition in the Primary Ciliary Dyskinesia (PCD) market.

1. Key Insights

2. Primary Ciliary Dyskinesia: Epidemiology Overview at a Glance

3. Primary Ciliary Dyskinesia: Market Overview at a Glance

3.1 Total Market Share (%) Distribution of Primary Ciliary Dyskinesia in 2017

3.2 Total Market Share (%) Distribution of Primary Ciliary Dyskinesia in 2028

4. Primary Ciliary Dyskinesia (PCD): Disease Background and Overview

4.1 Introduction

4.2 Causes

4.3 Risk Factors

4.4 Signs and Symptoms

5. Inheritance pattern

5.1 Disease Manifestations

5.2 Genetics

5.3 Pathophysiology

5.3.1 Structure and function of cilia

5.3.2 Ciliary ultrastructural defects

5.3.3 Proposed Pathogenesis of Primary Ciliary Dyskinesia Lung Disease

5.4 Related Disorders

5.5 Diagnostic Approach

5.5.1 Diagnostic Tests

5.5.2 Recommended PCD Diagnostic Criteria by Age

5.5.3 Tests Not Recommended for PCD Diagnosis

5.5.4 European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia

5.6 North American Primary Ciliary Dyskinesia (PCD) Foundation guidelines

5.7 A comparison between the European Respiratory Society (ERS) and North American primary ciliary dyskinesia (PCD) Foundation guidelines

5.8 American Thoracic Society (ATS) Guideline Aids in Diagnosing Primary Ciliary Dyskinesia

5.8.1 Primary Ciliary Dyskinesia (PCD) Management

5.8.2 Diagnostic algorithm for Primary Ciliary Dyskinesia

5.9 Future Prospects of Primary Ciliary Dyskinesia Diagnosis

6. Treatment

6.1 Treatment Algorithm

6.2 Manifestation-wise Treatment

6.2.1 Respiratory Manifestations Treatment

6.2.2 Ear, nose and throat problems in PCD

6.2.3 Other Systems

7. Unmet Needs

8. Organizations contributing toward PCD

9. KOL's Views: Primary Ciliary Dyskinesia

10. Key Cross Competitors

11. Emerging Therapies

11.1 VX-371: Vertex Pharmaceuticals

11.1.1 Product Description

11.1.2 Other development Activities

11.1.3 Clinical Development

11.1.4 Product Profile

11.2 POL6014: Santhera Pharmaceuticals

11.2.1 Product Description

11.2.2 Other development Activities

11.2.3 Product Profile

11.3 Primary Ciliary Dyskinesia Research Program: Translate Bio

11.3.1 Product Description

11.3.2 Product Profile

11.4 SNSP113: Synspira Therapeutics

11.4.1 Product Description

11.4.2 Other development Activities

11.4.3 Clinical Development

11.4.4 Product Profile

11.5 ELX-02: Eloxx Pharmaceuticals

11.5.1 Product Description

11.5.2 Other development Activities

11.5.3 Product Profile

11.6 Future Treatment Therapies for Primary Ciliary Dyskinesia

12. Epidemiology and Patient Population

12.1 Key Findings

13. 7MM Total Prevalent Patient Population of PCD

14. Country Wise-Epidemiology of Primary Ciliary Dyskinesia

14.1 United States

14.1.1 Assumptions and Rationale

14.1.2 Total Prevalent Population of Primary Ciliary Dyskinesia

14.1.3 Total Diagnosed Population of Primary Ciliary Dyskinesia

14.1.4 Clinical Manifestations of Primary Ciliary Dyskinesia

14.2 EU5 Countries

14.2.1 Assumptions and Rationale

14.3 Germany

14.3.1 Total Prevalent Population of Primary Ciliary Dyskinesia

14.3.2 Total Diagnosed Population of Primary Ciliary Dyskinesia

14.3.3 Clinical Manifestations of Primary Ciliary Dyskinesia

14.4 France

14.4.1 Total Prevalent Population of Primary Ciliary Dyskinesia

14.4.2 Total Diagnosed Population of Primary Ciliary Dyskinesia

14.4.3 Clinical Manifestations of Primary Ciliary Dyskinesia

14.5 Italy

14.5.1 Total Prevalent Population of Primary Ciliary Dyskinesia

14.5.2 Total Diagnosed Population of Primary Ciliary Dyskinesia

14.5.3 Clinical Manifestations of Primary Ciliary Dyskinesia

14.6 Spain

14.6.1 Total Prevalent Population of Primary Ciliary Dyskinesia

14.6.2 Total Diagnosed Population of Primary Ciliary Dyskinesia

14.6.3 Clinical Manifestations of Primary Ciliary Dyskinesia

14.7 United Kingdom

14.7.1 Total Prevalent Population of Primary Ciliary Dyskinesia

14.7.2 Total Diagnosed Population of Primary Ciliary Dyskinesia

14.7.3 Clinical Manifestations of Primary Ciliary Dyskinesia

14.8 Japan

14.8.1 Assumptions and Rationale

14.8.2 Total Prevalent Population of Primary Ciliary Dyskinesia

14.8.3 Total Diagnosed Population of Primary Ciliary Dyskinesia

14.8.4 Clinical Manifestations of Primary Ciliary Dyskinesia

15. Case-Reports

15.1 Diagnostic Journey of a girl who couldn't stop coughing

15.2 Early Lung Disease in Young Children with Primary Ciliary Dyskinesia - Therapeutic Perspective

15.3 Ultrastructural pathology of primary ciliary dyskinesia: report about 125 cases in Germany - Diagnostic Perspective

15.4 Individualized physical training in the therapy of Primary Ciliary Dyskinesia - A case report - Preventive Therapy Perspective

15.5 Kartagener's syndrome

15.6 Nasal nitric oxide is low early in life: case study of two infants with primary ciliary dyskinesia

16. Projects aimed to push the research of Primary Ciliary Dyskinesia forward

16.1 BESTCILIA Project (Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia) - December 2012 - May 2016 (Duration 42 months)

16.1.1 Executive Summary

16.1.2 Project Context and Objectives

16.1.3 Project Results

16.1.4 Potential Impact

16.1.5 Dissemination of project results - discourse with the scientific community

16.1.6 Funding

16.2 BEAT - PCD (Better Experimental Approaches to Treat Primary Ciliary Dyskinesia)

16.2.1 Introduction

16.2.2 Objectives

16.2.3 Proceedings of the COST action BM1407 inaugural conference BEAT-PCD: translational research in primary ciliary dyskinesia - bench, bedside, and population perspectives - Summary

17. Primary Ciliary Dyskinesia: 7 Major Market Analysis

17.1 Key Findings

17.2 Market Size of Primary Ciliary Dyskinesia in 7MM

17.2.1 Total Market Size of Primary Ciliary Dyskinesia

17.2.2 Market Size of Primary Ciliary Dyskinesia by Therapies

18. United States Market Outlook

18.1.1 United States Market Size

18.1.2 Total Market Size of Primary Ciliary Dyskinesia

18.1.3 Market Size of Primary Ciliary Dyskinesia by Therapies

19. EU-5 Countries: Market Outlook

19.1 Germany

19.1.1 Total Market size of Primary Ciliary Dyskinesia

19.1.2 Market Size of Primary Ciliary Dyskinesia by Therapies

19.2 France

19.2.1 Total Market Size of Primary Ciliary Dyskinesia

19.2.2 Market Size of Primary Ciliary Dyskinesia by Therapies

19.3 Italy

19.3.1 Total Market Size of Primary Ciliary Dyskinesia

19.3.2 Market Size of Primary Ciliary Dyskinesia by Therapies

19.4 Spain

19.4.1 Total Market Size of Primary Ciliary Dyskinesia

19.4.2 Market Size of Primary Ciliary Dyskinesia by Therapies

19.5 United Kingdom

19.5.1 Total Market Size of Primary Ciliary Dyskinesia

19.5.2 Market Size of Primary Ciliary Dyskinesia by Therapies

20. Japan: Market Outlook

20.1 Total Market Size of Primary Ciliary Dyskinesia

20.2 Market Size of Primary Ciliary Dyskinesia by Therapies

21. Market Drivers

22. Market Barriers

23. Appendix

23.1 Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

Table 1 Genes associated with Primary Ciliary Dyskinesia and corresponding ultrastructure

Table 2 Recommended Diagnostic Testing Methods for Primary Ciliary Dyskinesia

Table 3 Tests NOT Recommended for Diagnosing Primary Ciliary Dyskinesia

Table 4 Other Chronic Respiratory Conditions to Consider When Considering a Diagnosis of PCD

Table 5 Other Diseases Co?Segregating With PCD

Table 6 Recommended Diagnostic Testing Methods for Primary Ciliary Dyskinesia

Table 7 Tests NOT Recommended for Diagnosing Primary Ciliary Dyskinesia

Table 8 Other Chronic Respiratory Conditions to Consider When Considering a Diagnosis of PCD

Table 9 Other Diseases Co-Segregating With PCD

Table 10 Suggested Schedule of Investigations and Clinical Care in Primary Ciliary Dyskinesia

Table 11 Comparison of European Respiratory Society & North American PCD Foundation guidelines

Table 12 Summary table of lower respiratory treatment recommendations in PCD

Table 13 Organizations contributing toward PCD

Table 14 Comparison Of Drugs Under Development For Primary Ciliary Dyskinesia

Table 15 VX-371 Clinical Trial Description, 2019

Table 16 Total Prevalent Population of PCD in the 7MM (2017-2028)

Table 17 Total Prevalent Population of PCD in the US (2017-2028)

Table 18 Diagnosed Cases of PCD in the US (2017-2028)

Table 19 Clinical Mannifestations associated with Primary Ciliary Dyskine in the US (2017-2028)

Table 20 Situs Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 21 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 22 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 23 Other Manifestations associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 24 Total Prevalent Population of PCD in Germany (2017-2028)

Table 25 Diagnosed Cases of PCD in Germany (2017-2028)

Table 26 Clinical Mannifestations associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 27 Situs Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 28 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 29 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 30 Other Manifestations associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 31 Total Prevalent Population of PCD in France (2017-2028)

Table 32 Diagnosed Cases of PCD in France (2017-2028)

Table 33 Clinical Mannifestations associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 34 Situs Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 35 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 36 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 37 Other Manifestations associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 38 Total Prevalent Population of PCD in Italy (2017-2028)

Table 39 Diagnosed Cases of PCD in Italy (2017-2028)

Table 40 Clinical Manifestations associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 41 Situs Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 42 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 43 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 44 Other Manifestations associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 45 Total Prevalent Population of PCD in Spain (2017-2028)

Table 46 Diagnosed Cases of PCD in Spain (2017-2028)

Table 47 Clinical Manifestations associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 48 Situs Anomalies associated with Primary Ciliary Dyskinesia in Spain(2017-2028)

Table 49 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 50 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 51 Other Manifestations associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 52 Total Prevalent Population of PCD in United Kingdom (2017-2028)

Table 53 Diagnosed Cases of PCD in United Kingdom (2017-2028)

Table 54 Clinical Mannifestations associated with Primary Ciliary Dyskinesia in the United Kingdom (2017-2028)

Table 55 Situs Anomalies associated with PCD in United Kingdom (2017-2028)

Table 56 Lower Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)

Table 57 Upper Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)

Table 58 Other Manifestations associated with PCD in United Kingdom (2017-2028)

Table 59 Total Prevalent Population of PCD in Japan (2017-2028)

Table 60 Diagnosed Cases of PCD in Japan (2017-2028)

Table 61 Clinical Manifestations associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 62 Situs Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 63 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 64 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 65 Other Manifestations associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 66 7 Major Market Size of Primary Ciliary Dyskinesia in USD Million ( 2017-2028)

Table 67 7 Major Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million ( 2017-2028)

Table 68 Total Market Size of Primary Ciliary Dyskinesia in the United States (2017-2028)

Table 69 The United States Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million (2017-2028)

Table 70 Total Market Size of Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 71 Germany Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million ( 2017-2028)

Table 72 Total Market Size of Primary Ciliary Dyskinesia in France (2017-2028)

Table 73 France Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million ( 2017-2028)

Table 74 Total Market Size of Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 75 Italy Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million (2017-2028)

Table 76 Total Market Size of Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 77 Spain Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million (2017-2028)

Table 78 Total Market Size of Primary Ciliary Dyskinesia in United Kingdom (2017-2028)

Table 79 United Kingdom Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million (2017-2028)

Table 80 Total Market Size of Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 81 The United States Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million ( 2017-2028)

Figure 1: Total Prevalent Population of PCD in the 7 MM (2017)

Figure 2: Total Prevalent Population of PCD in the 7 MM (2028)

Figure 3: Total Market Share (%) Distribution of Primary Ciliary Dyskinesia in 2017

Figure 4: Total Market Share (%) Distribution of Primary Ciliary Dyskinesia in 2028

Figure 5: Organs affected by Primary Ciliary Dyskinesia

Figure 6: Risk Factors of Primary Ciliary Dyskinesis

Figure 7: Symptoms associated with Primary Ciliary Dyskinesia

Figure 8: Inheritance Pattern of PCD

Figure 9: The classical clinical phenotypes of Primary Ciliary Dyskinesia at various ages

Figure 10: The classical clinical phenotypes of Primary Ciliary Dyskinesia at various ages

Figure 11: Proposed pathogenesis of primary ciliary dyskinesia lung disease

Figure 12: PCD classification according to the European Respiratory Society guidelines for the diagnosis of PCD.

Figure 13: Algorithm for diagnostic assessment of patients for PCD proposed by the ERS Task Force

Figure 14: Further steps after diagnostic workup and management for patients

Figure 15: Diagnostic algorithm for primary ciliary dyskinesia

Figure 16: The National Health Services England: PCD Management

Figure 17: The National Health Services England: PCD Management

Figure 18: Unmet Needs of Primary Ciliary Dyskinesia

Figure 19: Total Prevalent Patient Population of PCD in the 7MM (2017-2028)

Figure 20: Total Prevalent Population of PCD in the US (2017-2028)

Figure 21: Diagnosed Cases of PCD in the US (2017-2028)

Figure 22: Clinical Manifestations of PCD in the US (2017-2028)

Figure 23 Situs Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Figure 24 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Figure 25 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Figure 26: Other Manifestations associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Figure 27: Total Prevalent Population of PCD in Germany (2017-2028)

Figure 28: Diagnosed Cases of PCD in Germany (2017-2028)

Figure 29: Clinical Manifestations of PCD in Germany (2017-2028)

Figure 30 Situs Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Figure 31 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Figure 32 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Figure 33: Other Manifestations associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Figure 34: Total Prevalent Population of PCD in France (2017-2028)

Figure 35: Diagnosed Cases of PCD in France (2017-2028)

Figure 36: Clinical Manifestations of PCD in France (2017-2028)

Figure 37 Situs Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Figure 38 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Figure 39 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Figure 40: Other Manifestations associated with Primary Ciliary Dyskinesia in France (2017-2028)

Figure 41: Total Prevalent Population of PCD in Italy (2017-2028)

Figure 42: Diagnosed Cases of PCD in Italy (2017-2028)

Figure 43: Clinical Manifestations of PCD in Italy (2017-2028)

Figure 44 Situs Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Figure 45 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Figure 46 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Figure 47: Other Manifestations associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Figure 48: Total Prevalent Population of PCD in Spain (2017-2028)

Figure 49: Diagnosed Cases of PCD in Spain (2017-2028)

Figure 50: Clinical Manifestations of PCD in Spain (2017-2028)

Figure 51 Situs Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Figure 52 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Figure 53 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Figure 54: Other Manifestations associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Figure 55: Total Prevalent Population of PCD in United Kingdom (2017-2028)

Figure 56: Diagnosed Cases of PCD in United Kingdom (2017-2028)

Figure 57: Clinical Manifestations of PCD in United Kingdom (2017-2028)

Figure 58 Situs Anomalies associated with PCD in United Kingdom (2017-2028)

Figure 59 Lower Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)

Figure 60 Upper Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)

Figure 61: Other Manifestations associated with PCD in United Kingdom (2017-2028)

Figure 62: Total Prevalent Population of PCD in Japan (2017-2028)

Figure 63: Diagnosed Cases of PCD in Japan (2017-2028)

Figure 64: Clinical Manifestations of PCD in Japan (2017-2028)

Figure 65: Situs Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Figure 66: Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Figure 67:       Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Figure 68:     Other Manifestations associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Figure 69:     Diagram of BEAT-PCD Workgroups (WG), overall aims and training opportunities

Figure 70:     Susana Lopes from the Nova Medical School, Universidade Nova de Lisboa, Portugal presented on in vivo models of PCD

Figure 71:      Mary Carroll from University Hospital Southampton, UK presented on the microbiome-pointers from CF

Figure 72:     Cecilia Lo from the School of Medicine, University of Pittsburgh, USA presented on pulmonary morbidity in congenital heart disease and the shared genetic aetiology of PCD and heterotaxy

Figure 73:     Claudia Kuehni from the Institute of Social and Preventive Medicine, University of Bern, Switzerland highlighted open questions, gaps and controversies in PCD epidemiology

Figure 74:   Kim G. Nielsen from the Danish PCD Centre and Paediatric Pulmonary Service, Copenhagen University Hospital, Denmark presented on Pseudomonas infection - a growing problem in PCD

Figure 75:    Hannah Mitchison from University College London, UK presented on PCD genetics as diagnostic test

Figure 76:   Laura Behan from University of Southamton, UK and University College Cork, Ireland presented on Health related quality of life measures for PCD: QOL-PCD

Figure 77:   Philipp Latzin from the University of Bern and the University of Basel, Switzerland presented on multiple-breath washout

Figure 78:  Oliver Bieri from the University of Basel, Switzerland presented on lung MRI: overview and application in PCD

Figure 79:  Egbert Biesheuvel from the FP7 ASTERIX project presented on methodological approaches to overcome the difficulties of conducting research in rare diseases

Figure 80:   7 Major Market Size of PCD in USD Million ( 2017-2028)

Figure 81:   7 Major Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million (2017-2028)

Figure 82:  The United States Market Size of PCD in USD Million ( 2017-2028)

Figure 83:  The US Market Size of PCD by Therapies in USD Million (2017-2028)

Figure 84:   Market Size of PCD in Germany, USD Million (2017-2028)

Figure 85:   Germany Market Size of PCD by Therapies in USD Million (2017-2028)

Figure 86:   Market Size of PCD in France USD Million ( 2017-2028)

Figure 87:   France Market Size of PCD by Therapies in USD Million ( 2017-2028)

Figure 88:   Market Size of PCD in Italy, USD Million ( 2017-2028)

Figure 89:   Italy Market Size of PCD by Therapies in USD Million (2017-2028)

Figure 90:   Market Size of PCD in Spain, USD Million (2017-2028)

Figure 91:   Spain Market Size of PCD by Therapies in USD Million (2017-2028)

Figure 92:   Market Size of PCD in the United Kingdom, USD Million (2017-2028)

Figure 93:   The UK Market Size of PCD by Therapies in USD Million (2017-2028)

Figure 94:   Market Size of PCD in Japan, USD Million (2017-2028)

Figure 95:    The UK Market Size of PCD by Therapies in USD Million (2017-2028)

Figure 96:     Market Drivers

Figure 97:    Market Barriers

  • Tags:
  • Primary Ciliary Dyskinesia market
  • Primary Ciliary Dyskinesia market r...
  • Primary Ciliary Dyskinesia market i...
  • Primary Ciliary Dyskinesia market t...
  • Primary Ciliary Dyskinesia market f...
  • Primary Ciliary Dyskinesia market s...
  • Primary Ciliary Dyskinesia pipeline...
  • Primary Ciliary Dyskinesia treatmen...
  • Primary Ciliary Dyskinesia drugs
  • Primary Ciliary Dyskinesia sales fo...
  • Primary Ciliary Dyskinesia market s...
  • Primary Ciliary Dyskinesia disease
  • Primary Ciliary Dyskinesia epidemio...
  • Primary Ciliary Dyskinesia
  • Primary Ciliary Dyskinesia Companie...
  • Primary Ciliary Dyskinesia Pipelin...

Forward to Friend

Need A Quote